Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, discusses the PALOMA3 trial.
Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, Jefferson University Hospital, discusses the PALOMA3 trial.
The randomized, placebo-controlled phase III study examined palbociclib plus fulvestrant in pre- and post-menopausal patients with ER-positive breast cancer. The first analysis demonstrated that the primary endpoint, which was progression-free survival (PFS), had been reached. In the combination arm, PFS was 9.2 months compared to 3.8 months in the control arm, Cristofanilli says.
Patients treated with the combination previously failed endocrine therapy in the metastatic setting. One line of chemotherapy in the metastatic setting was permitted. Results of the study showed that the addition of palbociclib to fulvestrant is a more effective treatment versus fulvestrant alone, Cristofanilli says.